Manuel de la Torre-Aláez

7PUBLICATIONS
20CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMetabolic medicineRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 19, 2026
Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.

Belén Aparicio, Leyre Silva, Marta Ruiz

|Sep 13, 2025
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?

Lucía Ceniceros, Manuel de La Torre, Ana Landa Magdalena

|Apr 08, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial.

Manuel De la Torre-Aláez, Ana Matilla, María Varela

|May 22, 2024
The 'BCLC upon progression' classification: After repeated validation, it is time to incorporate it in trial design.

Manuel de la Torre-Aláez, Maria Reig

|Mar 28, 2023
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.

Paloma Sangro, Manuel de la Torre Aláez, Bruno Sangro

|Nov 30, 2022
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study.

Manuel de la Torre-Aláez, Ana Matilla, Maria Varela

Pageof 2

Frequent Collaborators

4 joint publications

Bruno Sangro

2 joint publications

Paloma Sangro

2 joint publications

Josepmaria Argemí

2 joint publications

Macarena Rodriguez-Fraile